Lundbeck CEO says Alzheimer's drug could be U.S. blockbuster

COPENHAGEN, March 26 Tue Mar 26, 2013 8:51am EDT

Related Topics

COPENHAGEN, March 26 (Reuters) - Danish pharmaceutical group Lundbeck said its Alzheimer's treatment Lu AE58054 had the potential to become a blockbuster and generate over $1 billion per year in the United States.

Lundbeck announced a deal earlier on Tuesday granting Japan's Otsuka the rights to joint development and commercialization of the drug, and Chief Executive Ulf Wiinberg said he also saw potential for more such deals.

"Lu AE58054 is the first one that we do, but potentially there can be two more," Wiinberg said. (Reporting by Stine Jacobsen)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

California state worker Albert Jagow (L) goes over his retirement options with Calpers Retirement Program Specialist JeanAnn Kirkpatrick at the Calpers regional office in Sacramento, California October 21, 2009. Calpers, the largest U.S. public pension fund, manages retirement benefits for more than 1.6 million people, with assets comparable in value to the entire GDP of Israel. The Calpers investment portfolio had a historic drop in value, going from a peak of $250 billion in the fall of 2007 to $167 billion in March 2009, a loss of about a third during that period. It is now around $200 billion. REUTERS/Max Whittaker   (UNITED STATES) - RTXPWOZ

How to get out of debt

Financial adviser Eric Brotman offers strategies for cutting debt from student loans and elder care -- and how to avoid money woes in the first place.  Video